Advertisement

AAPS PharmSciTech

, Volume 19, Issue 8, pp 3886–3894 | Cite as

In Vivo Evaluation of Taste-Masked Fast-Disintegrating Sublingual Tablets of Epinephrine Microcrystals

  • Ousama Rachid
  • Keith J. Simons
  • Mutasem Rawas-Qalaji
Research Article

Abstract

In community settings, IM injection of 0.3 mg epinephrine (Epi) using an auto-injector is the drug of choice for treatment of anaphylaxis. Previously, a taste-masking (TM) formulation of fast-disintegrating sublingual tablets (FDSTs) was developed in our lab. Also, Epi was micronized (Epi-MC) successfully and reduced the previously achieved bioequivalent sublingual Epi dose to 0.3 mg IM injection by half using non-taste-masked fast-disintegrating sublingual tablets (TM-FDSTs). Our objective for this study was to evaluate the sublingual absorption of Epi-MC using TM-FDST. These sublingual Epi tablets have potential for out-of-hospital treatment of anaphylaxis and are suitable for human studies. TM-FDSTs containing Epi-MC were manufactured by direct compression. The rate and extent of Epi absorption from our developed 20 mg Epi-MC-TM-FDSTs (n = 5) were evaluated in rabbits and compared to the previous result from 20 mg Epi-MC in non-TM-FDSTs and EpiPen® auto-injector. Blood samples were collected over 1 h, and Epi concentrations were measured using HPLC with electrochemical detection. Mean ± SEM AUC0–1 h and Cmax from 20 mg Epi-MC-TM-FDSTs (733 ± 78 ng/ml/min and 30 ± 8 ng/ml) and 20 mg Epi-MC-non-TM-FDSTs (942 ± 109 ng/ml/min and 38 ± 4 ng/ml) were not significantly different (p > 0.05) from each other or from EpiPen® (592 ± 50 ng/ml/min and 28 ± 3 ng/ml) but were significantly higher (p < 0.05) than endogenous Epi after placebo FDSTs (220 ± 32 ng/ml/min and 8 ± 1 ng/ml). Mean ± SD Tmax was not significantly different (p > 0.05) among all formulations. Epi-MC-TM-FDSTs formulation improved Epi absorption twofold and reduced the required bioequivalent dose by 50%, similar to results obtained using non-TM-FDSTs. The incorporation of TM excipients did not interfere with the absorption of Epi-MC.

KEY WORDS

absorption adrenaline anaphylaxis epinephrine microcrystals sublingual tablets 

Notes

Compliance with Ethical Standards

The protocol for the in vivo study, which was performed in a validated rabbit model, was reviewed and approved by the Protocol Management and Review Committee in the University of Manitoba. The guidelines of the Canadian Council on Animal Care were followed (36).

Conflict of Interest

The authors declare that they have no conflict of interest.

References

  1. 1.
    Simons FE, Ardusso LR, Bilò MB, El-Gamal YM, Ledford DK, Ring J, et al. World Allergy Organization anaphylaxis guidelines: summary. J Allergy Clin Immunol. 2011;127(3):587–93.e1–22.  https://doi.org/10.1016/j.jaci.2011.01.038.CrossRefPubMedGoogle Scholar
  2. 2.
    Lieberman PI, Nicklas RA, Oppenheimer J, Kemp SF, Lang DM, Bernstein DI, et al. The diagnosis and management of anaphylaxis practice parameter: 2010 update. J Allergy Clin Immunol. 2010;126(3):477–80.e1–42.  https://doi.org/10.1016/j.jaci.2010.06.022.CrossRefPubMedGoogle Scholar
  3. 3.
    Fleming JT, Clark S, Camargo CA Jr, Rudders SA. Early treatment of food-induced anaphylaxis with epinephrine is associated with a lower risk of hospitalization. J Allergy Clin Immunol Pract. 2015;3(1):57–62.  https://doi.org/10.1016/j.jaip.2014.07.004.CrossRefPubMedGoogle Scholar
  4. 4.
    Chooniedass R, Temple B, Becker A. Epinephrine use for anaphylaxis: too seldom, too late: current practices and guidelines in health care. Ann Allergy Asthma Immunol. 2017;119(2):108–10.  https://doi.org/10.1016/j.anai.2017.06.004.CrossRefPubMedGoogle Scholar
  5. 5.
    Simons KJ, Simons FE. Epinephrine and its use in anaphylaxis: current issues. Curr Opin Allergy Clin Immunol. 2010;4:354–61.  https://doi.org/10.1097/ACI.0b013e32833bc670.CrossRefGoogle Scholar
  6. 6.
    Edwards ES, Gunn R, Simons ER, Carr K, Chinchilli VM, Painter G, et al. Bioavailability of epinephrine from Auvi-Q compared with EpiPen. Ann Allergy Asthma Immunol. 2013;111(2):132–7.  https://doi.org/10.1016/j.anai.2013.06.002.CrossRefPubMedGoogle Scholar
  7. 7.
    Brown C. Initial confusion after massive Allerject recall. CMAJ. 2015;187(18):E509–10.  https://doi.org/10.1503/cmaj.109-5194.CrossRefPubMedPubMedCentralGoogle Scholar
  8. 8.
    Palmer E. FDA slams Pfizer unit responsible for EpiPens that failed during fatal emergencies. In: FiercePharma, Questex LLC. 2017. https://www.fiercepharma.com/pharma/fda-slams-pfizer-unit-made-epipens-failed-during-fatal-emergencies. Accessed 6 Oct 2017.
  9. 9.
    Scutti S. ‘Short-term’ EpiPen shortage, anticipates FDA. In: Cable News Network. Turner Broadcasting System, Inc. 2018. https://edition.cnn.com/2018/05/09/health/epipen-fda-drug-shortages-list-bn/index.html. Accessed 6 Jun 2018.
  10. 10.
    Kim L, Nevis IF, Tsai G, Dominic A, Potts R, Chiu J, et al. Children under 15 kg with food allergy may be at risk of having epinephrine auto-injectors administered into bone. Allergy Asthma Clin Immunol. 2014;10(1):40.  https://doi.org/10.1186/1710-1492-10-40.CrossRefPubMedPubMedCentralGoogle Scholar
  11. 11.
    Dreborg S, Wen X, Kim L, Tsai G, Nevis I, Potts R, et al. Do epinephrine auto-injectors have an unsuitable needle length in children and adolescents at risk for anaphylaxis from food allergy? Allergy Asthma Clin Immunol. 2016;12:11.  https://doi.org/10.1186/s13223-016-0110-8.CrossRefPubMedPubMedCentralGoogle Scholar
  12. 12.
    Noimark L, Wales J, Du Toit G, Pastacaldi C, Haddad D, Gardner J, et al. The use of adrenaline autoinjectors by children and teenagers. Clin Exp Allergy. 2012;42(2):284–92.  https://doi.org/10.1111/j.1365-2222.2011.03912.x.CrossRefPubMedGoogle Scholar
  13. 13.
    Simons FE, Clark S, Camargo CA Jr. Anaphylaxis in the community: learning from the survivors. J Allergy Clin Immunol. 2009;124(2):301–6.  https://doi.org/10.1016/j.jaci.2009.03.050.CrossRefPubMedGoogle Scholar
  14. 14.
    Brown JC, Tuuri RE, Akhter S, Guerra LD, Goodman IS, Myers SR, et al. Lacerations and embedded needles caused by epinephrine autoinjector use in children. Ann Emerg Med. 2016;67(3):307–15.  https://doi.org/10.1016/j.annemergmed.2015.07.011.CrossRefPubMedGoogle Scholar
  15. 15.
    Hawkins SC, Weil C, Baty F, Fitzpatrick D, Rowell B. Retrieval of additional epinephrine from auto-injectors. Wilderness Environ Med. 2013;24(4):434–44.  https://doi.org/10.1016/j.wem.2013.03.025.CrossRefPubMedGoogle Scholar
  16. 16.
    Robinson PE, Lareau SA. Novel technique for epinephrine removal in new generation autoinjectors. Wilderness Environ Med. 2016;27(2):252–5.  https://doi.org/10.1016/j.wem.2016.02.005.CrossRefPubMedGoogle Scholar
  17. 17.
    Frechen S, Suleiman AA, Mohammad Nejad Sigaroudi A, Wachall B, Fuhr U. Population pharmacokinetic and pharmacodynamic modeling of epinephrine administered using a mobile inhaler. Drug Metab Pharmacokinet. 2015;30(6):391–9.  https://doi.org/10.1016/j.dmpk.2015.08.002.CrossRefPubMedGoogle Scholar
  18. 18.
    Simons FE, Gu X, Johnston LM, Simons KJ. Can epinephrine inhalations be substituted for epinephrine injection in children at risk for systemic anaphylaxis? Pediatrics. 2000;106(5):1040–4.CrossRefPubMedGoogle Scholar
  19. 19.
    Rawas-Qalaji MM, Simons FE, Simons KJ. Sublingual epinephrine tablets versus intramuscular injection of epinephrine: dose equivalence for potential treatment of anaphylaxis. J Allergy Clin Immunol. 2006;117(2):398–403.  https://doi.org/10.1016/j.jaci.2005.12.1310.CrossRefPubMedGoogle Scholar
  20. 20.
    Rawas-Qalaji MM, Simons FE, Simons KJ. Epinephrine for the treatment of anaphylaxis: do all 40 mg sublingual epinephrine tablet formulations with similar in vitro characteristics have the same bioavailability? Biopharm Drug Dispos. 2006;27(9):427–35.  https://doi.org/10.1002/bdd.519.CrossRefPubMedGoogle Scholar
  21. 21.
    Rawas-Qalaji MM, Simons FE, Simons KJ. Fast-disintegrating sublingual tablets: effect of epinephrine load on tablet characteristics. AAPS PharmSciTech. 2006;7(2):E41.  https://doi.org/10.1208/pt070241.CrossRefPubMedGoogle Scholar
  22. 22.
    Rawas-Qalaji MM, Simons FE, Simons KJ. Fast-disintegrating sublingual epinephrine tablets: effect of tablet dimensions on tablet characteristics. Drug Dev Ind Pharm. 2007;33(5):523–30.  https://doi.org/10.1080/03639040600897150.CrossRefPubMedGoogle Scholar
  23. 23.
    Rachid O, Simons FE, Rawas-Qalaji MM, Simons KJ. An electronic tongue: evaluation of the masking efficacy of sweetening and/or flavoring agents on the bitter taste of epinephrine. AAPS PharmSciTech. 2010;11(2):550–7.  https://doi.org/10.1208/s12249-010-9402-3.CrossRefPubMedPubMedCentralGoogle Scholar
  24. 24.
    Rachid O, Rawas-Qalaji M, Simons FE, Simons KJ. Dissolution testing of sublingual tablets: a novel in vitro method. AAPS PharmSciTech. 2011;12(2):544–52.  https://doi.org/10.1208/s12249-011-9615-0.CrossRefPubMedPubMedCentralGoogle Scholar
  25. 25.
    Rachid O, Rawas-Qalaji M, Simons FE, Simons KJ. Rapidly-disintegrating sublingual tablets of epinephrine: role of non-medicinal ingredients in formulation development. Eur J Pharm Biopharm. 2012;28(3):598–604.  https://doi.org/10.1016/j.ejpb.2012.05.020.CrossRefGoogle Scholar
  26. 26.
    Rachid O, Rawas-Qalaji M, Simons FE, Simons KJ. Epinephrine (adrenaline) absorption from new-generation, taste-masked sublingual tablets: a preclinical study. J Allergy Clin Immunol. 2013;131(1):236–8.  https://doi.org/10.1016/j.jaci.2012.10.016.CrossRefPubMedGoogle Scholar
  27. 27.
    Rawas-Qalaji MM, Rachid O, Simons FE, Simons KJ. Long-term stability of epinephrine sublingual tablets for the potential first-aid treatment of anaphylaxis. Ann Allergy Asthma Immunol. 2013;111(6):568–70.  https://doi.org/10.1016/j.anai.2013.09.005.CrossRefPubMedGoogle Scholar
  28. 28.
    Rachid O, Rawas-Qalaji M, Simons KJ. Epinephrine in anaphylaxis: preclinical study of pharmacokinetics after sublingual administration of taste-masked tablets for potential pediatric use. Pharmaceutics. 2018;10(1):24.  https://doi.org/10.3390/pharmaceutics10010024.CrossRefPubMedCentralGoogle Scholar
  29. 29.
    Guez S. Efficacy of desensitization via the sublingual route in mite allergy. Chem Immunol Allergy. 2003;82:62–76.CrossRefPubMedGoogle Scholar
  30. 30.
    Bredenberg S, Duberg M, Lennernäs B, Lennernäs H, Pettersson A, Westerberg M, et al. In vitro and in vivo evaluation of a new sublingual tablet system for rapid oromucosal absorption using fentanyl citrate as the active substance. Eur J Pharm Sci. 2003;20(3):327–34.CrossRefPubMedGoogle Scholar
  31. 31.
    Glover ED, Glover PN, Franzon M, Sullivan CR, Cerullo CC, Howell RM, et al. A comparison of a nicotine sublingual tablet and placebo for smoking cessation. Nicotine Tob Res. 2002;4(4):441–50.CrossRefPubMedGoogle Scholar
  32. 32.
    Rawas-Qalaji M, Rachid O, Mendez BA, Losada A, Simons FE, Simons KJ. Adrenaline (epinephrine) microcrystal sublingual tablet formulation: enhanced absorption in a preclinical model. J Pharm Pharmacol. 2015;67(1):20–5.  https://doi.org/10.1111/jphp.12312.CrossRefPubMedGoogle Scholar
  33. 33.
    Rawas-Qalaji MM, Werdy S, Rachid O, Simons FE, Simons KJ. Sublingual diffusion of epinephrine microcrystals from rapidly disintegrating tablets for the potential first-aid treatment of anaphylaxis: in vitro and ex vivo study. AAPS PharmSciTech. 2015;16(5):1203–12.CrossRefPubMedPubMedCentralGoogle Scholar
  34. 34.
    Physical Tests. Uniformity of dosage units. In: USP/NF, 26/21 ed. Rockville: United States Pharmacopeial Convention Inc.; 2003.Google Scholar
  35. 35.
    Official Monograph. Epinephrine injection. In: USP/NF, 32/27 ed., Rockville: United States Pharmacopeial Convention Inc.; 2009. p. 2261.Google Scholar
  36. 36.
    Olfert ED, Cross BM, McWilliam AA. Guide to the care and use of experimental animals. 2nd ed. Canadian Council on Animal Care: Ottawa; 1993.Google Scholar
  37. 37.
    Hjemdahl P. Inter-laboratory comparison of plasma catecholamine determinations using several different assays. Acta Physiol Scand Suppl. 1984;527:43–54.PubMedGoogle Scholar
  38. 38.
    Hjemdahl P. Catecholamine measurements in plasma by high-performance liquid chromatography with electrochemical detection. Methods Enzymol. 1987;142:521–34.CrossRefPubMedGoogle Scholar
  39. 39.
    Ganhao MF, Hattingh J, Hurwitz ML, Pitts NI. Evaluation of a simple plasma catecholamine extraction procedure prior to high-performance liquid chromatography and electrochemical detection. J Chromatogr. 1991;564(1):55–66.CrossRefPubMedGoogle Scholar
  40. 40.
    Motosue MS, Bellolio MF, Van Houten HK, Shah ND, Campbell RL. Increasing emergency department visits for anaphylaxis, 2005–2014. J Allergy Clin Immunol Pract. 2016;5(1):171–5. e3.  https://doi.org/10.1016/j.jaip.2016.08.013.CrossRefPubMedGoogle Scholar
  41. 41.
    Munblit D, Treneva M, Korsunskiy I, Asmanov A, Pampura A, Warner JO. A national survey of Russian physicians’ knowledge of diagnosis and management of food-induced anaphylaxis. BMJ Open. 2017;7(7):e015901.  https://doi.org/10.1136/bmjopen-2017-015901.CrossRefPubMedPubMedCentralGoogle Scholar
  42. 42.
    Muraro A, Roberts G, Worm M, Bilò MB, Brockow K, Fernández Rivas M, et al. Anaphylaxis: guidelines from the European academy of allergy and clinical immunology. Allergy. 2014;69(8):1026–45.  https://doi.org/10.1111/all.12437.CrossRefPubMedGoogle Scholar
  43. 43.
    Chad L, Ben-Shoshan M, Asai Y, Cherkaoui S, Alizadehfar R, St-Pierre Y, et al. A majority of parents of children with peanut allergy fear using the epinephrine auto-injector. Allergy. 2013;68(12):1605–9.  https://doi.org/10.1111/all.12262.CrossRefPubMedGoogle Scholar
  44. 44.
    FDA In Brief: FDA takes additional action to mitigate shortages of EpiPen by extending expiration date for specific lots of medication. In U.S. Food and Drug Administration; Maryland (USA). 2018. https://www.fda.gov/NewsEvents/Newsroom/FDAInBrief/ucm617724.htm?utm_campaign=08212018_FiB_FDA%20extends%20expiry%20date%20for%20specific%20EpiPen%20lots%20to%20mitigate%20shortages&utm_medium=email&utm_source=Eloqua. Accessed 23 Aug 2018.
  45. 45.
    Rachid O, Simons FER, Rawas-Qalaji M, Lewis S, Simons KJ. Epinephrine doses delivered from auto-injectors stored at excessively high temperatures. Drug Dev Ind Pharm. 2016;42(1):131–5.CrossRefPubMedGoogle Scholar
  46. 46.
    Rachid O, Simons FER, Wein MB, Rawas-Qalaji MM, Simons KJ. Epinephrine doses contained in outdated epinephrine auto-injectors collected in a Florida allergy practice. Ann Allergy Asthma Immunol. 2015;114(4):354–6.  https://doi.org/10.1016/j.anai.2015.01.015.CrossRefPubMedGoogle Scholar
  47. 47.
    Rachid O, Simons FER, Rawas-Qalaji M, Lewis S, Simons KJ. Epinephrine autoinjectors: does freezing or refrigeration affect epinephrine dose delivery and enantiomeric purity? J Allergy Clin Immunol Pract. 2015;3(2):294–6.  https://doi.org/10.1016/j.jaip.2014.11.015.CrossRefPubMedGoogle Scholar
  48. 48.
    Hanson GR. Diuretic drugs. In: Gennaro AR, editor. Remington: the science and practice of pharmacy. Philadelphia: Lippincott Williams & Wilkins; 2000. p. 1344–53.Google Scholar
  49. 49.
    Gupta A, Khan MA. Challenges of pediatric formulations: a FDA science perspective. Int J Pharm. 2013;457(1):346–8.  https://doi.org/10.1016/j.ijpharm.2013.08.064.CrossRefPubMedGoogle Scholar
  50. 50.
    Committee for Medicinal Products for Human Use (CHMP). Reflection paper: formulations of choice for the paediatric population. EMEA/CHMP/PEG/194810/2005. In European Medicines Agency; London (UK). 2006. http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500003782.pdf. Accessed 11 Mar 2017.
  51. 51.
    Liem DG, Westerbeek A, Wolterink S, Kok FJ, de Graaf C. Sour taste preferences of children relate to preference for novel and intense stimuli. Chem Senses. 2004;29(8):713–20.  https://doi.org/10.1093/chemse/bjh077.CrossRefPubMedGoogle Scholar
  52. 52.
    Goel H, Rai P, Rana V, Tiwary AK. Orally disintegrating systems: innovations in formulation and technology. Recent Pat Drug Deliv Formul. 2008;2(3):258–74.CrossRefPubMedGoogle Scholar
  53. 53.
    Ayenew Z, Puri V, Kumar L, Bansal AK. Trends in pharmaceutical taste masking technologies: a patent review. Recent Pat Drug Deliv Formul. 2009;3(1):26–39.CrossRefPubMedGoogle Scholar

Copyright information

© American Association of Pharmaceutical Scientists 2018

Authors and Affiliations

  • Ousama Rachid
    • 1
  • Keith J. Simons
    • 2
  • Mutasem Rawas-Qalaji
    • 3
    • 4
  1. 1.College of PharmacyQatar UniversityDohaQatar
  2. 2.Faculty of PharmacyUniversity of ManitobaWinnipegCanada
  3. 3.College of PharmacyNova Southeastern UniversityFort LauderdaleUSA
  4. 4.Dr. Kiran C. Patel College of Allopathic MedicineNova Southeastern UniversityFort LauderdaleUSA

Personalised recommendations